The Development of mRNA Vaccines for Infectious Diseases: Recent Updates

References

• Greenwood B. The contribution of vaccination to global health: past, present and future. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130433. doi:10.1098/rstb.2013.043324821919
   PubMed Web of Science ®Google Scholar
• Minor PD. Live attenuated vaccines: historical successes and current challenges. Virology. 2015;479–480:379–392. doi:10.1016/j.virol.2015.03.032
   PubMed Web of Science ®Google Scholar
• Plett PC. [Peter Plett and other discoverers of cowpox vaccination before Edward Jenner]. Sudhoffs Arch. 2006;90:219–232. German.17338405
   PubMedGoogle Scholar
• Jenner E. Dr. Jenner, on the Vaccine Inoculation. Med Phys J. 1800;3:502–503.
   Google Scholar
• Pandey A, Cabello A, Akoolo L, et al. The case for live attenuated vaccines against the neglected zoonotic diseases brucellosis and bovine tuberculosis. PLoS Negl Trop Dis. 2016;10:e0004572. doi:10.1371/journal.pntd.000457227537413
   PubMed Web of Science ®Google Scholar
• Jang H, Elaish M, Kc M, et al. Efficacy and synergy of live-attenuated and inactivated influenza vaccines in young chickens. PLoS One. 2018;13:e0195285. doi:10.1371/journal.pone.019528529624615
   PubMed Web of Science ®Google Scholar
• Li J, Arevalo MT, Chen Y, Chen S, Zeng M. T-cell-mediated cross-strain protective immunity elicited by prime-boost vaccination with a live attenuated influenza vaccine. Int J Infect Dis. 2014;27:37–43. doi:10.1016/j.ijid.2014.05.01625172265
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261–279.29326426
   PubMed Web of Science ®Google Scholar
• Jirikowski GF, Sanna PP, Maciejewski-Lenoir D, Bloom FE. Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. Science. 1992;255:996–998. doi:10.1126/science.15462981546298
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang Z, Luo J, et al. mRNA vaccine: a potential therapeutic strategy. Mol Cancer. 2021;20:33. doi:10.1186/s12943-021-01311-z33593376
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Naradikian MS, et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018;215:1571–1588. doi:10.1084/jem.2017145029739835
   PubMed Web of Science ®Google Scholar
• Magini D, Giovani C, Mangiavacchi S, et al. Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge. PLoS One. 2016;11:e0161193. doi:10.1371/journal.pone.016119327525409
   PubMed Web of Science ®Google Scholar
• Brazzoli M, Magini D, Bonci A, et al. Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin. J Virol. 2016;90:332–344. doi:10.1128/JVI.01786-1526468547
   PubMed Web of Science ®Google Scholar
• McCullough KC, Bassi I, Milona P, et al. Self-replicating replicon-RNA delivery to dendritic cells by Chitosan-nanoparticles for translation in vitro and in vivo. Mol Ther Nucleic Acids. 2014;3:e173. doi:10.1038/mtna.2014.2425004099
   PubMedGoogle Scholar
• Hekele A, Bertholet S, Archer J, et al. Rapidly produced SAM ® vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect. 2013;2:e52. doi:10.1038/emi.2013.5426038486
   PubMed Web of Science ®Google Scholar
• Schnee M, Vogel AB, Voss D, et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl Trop Dis. 2016;10:e0004746. doi:10.1371/journal.pntd.000474627336830
   PubMed Web of Science ®Google Scholar
• Alberer M, Gnad-Vogt U, Hong HS, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390:1511–1520. doi:10.1016/S0140-6736(17)31665-328754494
   PubMed Web of Science ®Google Scholar
• Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol. 2012;9:1319–1330. doi:10.4161/rna.2226923064118
   PubMed Web of Science ®Google Scholar
• Andries O, Mc Cafferty S, De Smedt SC, et al. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release. 2015;217:337–344. doi:10.1016/j.jconrel.2015.08.05126342664
   PubMed Web of Science ®Google Scholar
• Kim J, Eygeris Y, Gupta M, Sahay G. Self-assembled mRNA vaccines. Adv Drug Deliv Rev. 2021;170:83–112. doi:10.1016/j.addr.2020.12.01433400957
   PubMed Web of Science ®Google Scholar
• Perri S, Greer CE, Thudium K, et al. An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol. 2003;77:10394–10403. doi:10.1128/JVI.77.19.10394-10403.200312970424
   PubMed Web of Science ®Google Scholar
• Fleeton MN, Chen M, Berglund P, et al. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis. 2001;183:1395–1398. doi:10.1086/31985711294672
   PubMed Web of Science ®Google Scholar
• Geall AJ, Verma A, Otten GR, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012;109:14604–14609. doi:10.1073/pnas.120936710922908294
   PubMed Web of Science ®Google Scholar
• Bogers WM, Oostermeijer H, Mooij P, et al. Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J Infect Dis. 2015;211:947–955. doi:10.1093/infdis/jiu52225234719
   PubMed Web of Science ®Google Scholar
• Martinon F, Krishnan S, Lenzen G, et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol. 1993;23:1719–1722. doi:10.1002/eji.18302307498325342
   PubMed Web of Science ®Google Scholar
• Petsch B, Schnee M, Vogel AB, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol. 2012;30:1210–1216. doi:10.1038/nbt.243623159882
   PubMed Web of Science ®Google Scholar
• Zhao M, Li M, Zhang Z, Gong T, Sun X. Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA. Drug Deliv. 2016;23:2596–2607. doi:10.3109/10717544.2015.103885626024387
   PubMed Web of Science ®Google Scholar
• Li M, Zhao M, Fu Y, et al. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways. J Control Release. 2016;228:9–19. doi:10.1016/j.jconrel.2016.02.04326941035
   PubMed Web of Science ®Google Scholar
• Kranz LM, Diken M, Haas H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:396–401. doi:10.1038/nature1830027281205
   PubMed Web of Science ®Google Scholar
• Linares-Fernandez S, Lacroix C, Exposito JY, Verrier B. Tailoring mRNA vaccine to balance innate/adaptive immune response. Trends Mol Med. 2020;26:311–323. doi:10.1016/j.molmed.2019.10.00231699497
   PubMed Web of Science ®Google Scholar
• Bahl K, Senn JJ, Yuzhakov O, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther. 2017;25:1316–1327. doi:10.1016/j.ymthe.2017.03.03528457665
   PubMed Web of Science ®Google Scholar
• Guevara ML, Persano F, Persano S. Advances in lipid nanoparticles for mRNA-based cancer immunotherapy. Front Chem. 2020;8:589959. doi:10.3389/fchem.2020.58995933195094
   PubMed Web of Science ®Google Scholar
• Eygeris Y, Patel S, Jozic A, Sahay G. Deconvoluting lipid nanoparticle structure for messenger RNA delivery. Nano Lett. 2020;20:4543–4549. doi:10.1021/acs.nanolett.0c0138632375002
   PubMed Web of Science ®Google Scholar
• Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7:319–334. doi:10.4155/tde-2016-000627075952
   PubMed Web of Science ®Google Scholar
• Edwards DK, Jasny E, Yoon H, et al. Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response. J Transl Med. 2017;15:1. doi:10.1186/s12967-016-1111-628049494
   PubMed Web of Science ®Google Scholar
• Maruggi G, Zhang C, Li J, Ulmer JB, Yu D. mRNA as a transformative technology for vaccine development to control infectious diseases. Mol Ther. 2019;27:757–772. doi:10.1016/j.ymthe.2019.01.02030803823
   PubMed Web of Science ®Google Scholar
• Maruggi G, Chiarot E, Giovani C, et al. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine. 2017;35:361–368. doi:10.1016/j.vaccine.2016.11.04027939014
   PubMed Web of Science ®Google Scholar
• Heine A, Juranek S, Brossart P. Clinical and immunological effects of mRNA vaccines in malignant diseases. Mol Cancer. 2021;20:52. doi:10.1186/s12943-021-01339-133722265
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589–593. doi:10.1038/s41586-020-2639-432785213
   PubMed Web of Science ®Google Scholar
• Pu J, Yu Q, Yin Z, et al. The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18–59 years: a phase I randomized, double-blinded, controlled trial. Vaccine. 2021;39:2746–2754. doi:10.1016/j.vaccine.2021.04.00633875266
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RW, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383:2439–2450. doi:10.1056/NEJMoa202790633053279
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615. doi:10.1056/NEJMoa203457733301246
   PubMed Web of Science ®Google Scholar
• Ji RR, Qu Y, Zhu H, et al. BNT162b2 vaccine encoding the SARS-CoV-2 P2 S protects transgenic hACE2 mice against COVID-19. Vaccines (Basel). 2021;9:324.33915773
   PubMed Web of Science ®Google Scholar
• Chen N, Xia P, Li S, et al. RNA sensors of the innate immune system and their detection of pathogens. IUBMB Life. 2017;69:297–304. doi:10.1002/iub.162528374903
   PubMed Web of Science ®Google Scholar
• Kowalczyk A, Doener F, Zanzinger K, et al. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. Vaccine. 2016;34:3882–3893. doi:10.1016/j.vaccine.2016.05.04627269061
   PubMed Web of Science ®Google Scholar
• Kell AM, Gale M. RIG-I in RNA virus recognition. Virology. 2015;479–480:110–121. doi:10.1016/j.virol.2015.02.017
   PubMed Web of Science ®Google Scholar
• Saito T, Gale M. Differential recognition of double-stranded RNA by RIG-I-like receptors in antiviral immunity. J Exp Med. 2008;205:1523–1527. doi:10.1084/jem.2008121018591413
   PubMed Web of Science ®Google Scholar
• Loo YM, Gale M. Immune signaling by RIG-I-like receptors. Immunity. 2011;34:680–692. doi:10.1016/j.immuni.2011.05.00321616437
   PubMed Web of Science ®Google Scholar
• Yin X, Riva L, Pu Y, et al. MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells. Cell Rep. 2021;34:108628. doi:10.1016/j.celrep.2020.10862833440148
   PubMed Web of Science ®Google Scholar
• Pollard C, Rejman J, De Haes W, et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther. 2013;21:251–259. doi:10.1038/mt.2012.20223011030
   PubMed Web of Science ®Google Scholar
• Lei X, Dong X, Ma R, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun. 2020;11:3810. doi:10.1038/s41467-020-17665-932733001
   PubMed Web of Science ®Google Scholar
• Park JW, Lagniton PNP, Liu Y, Xu RH. mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci. 2021;17:1446–1460. doi:10.7150/ijbs.5923333907508
   PubMed Web of Science ®Google Scholar
• Chatzikleanthous D, O’Hagan DT, Adamo R. Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines. Mol Pharm. 2021;18:2867–2888. doi:10.1021/acs.molpharmaceut.1c0044734264684
   PubMed Web of Science ®Google Scholar
• Cubas R, Zhang S, Kwon S, et al. Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother. 2009;32:118–128. doi:10.1097/CJI.0b013e31818f13c419238010
   PubMed Web of Science ®Google Scholar
• Lindgren G, Ols S, Liang F, et al. Induction of robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells. Front Immunol. 2017;8:1539. doi:10.3389/fimmu.2017.0153929181005
   PubMed Web of Science ®Google Scholar
• Cagigi A, Lore K. Immune responses induced by mRNA vaccination in mice, monkeys and humans. Vaccines (Basel). 2021;9. doi:10.3390/vaccines9010061
   Web of Science ®Google Scholar
• De Silva NS, Klein U. Dynamics of B cells in germinal centres. Nat Rev Immunol. 2015;15:137–148. doi:10.1038/nri380425656706
   PubMed Web of Science ®Google Scholar
• Hewitt EW. The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology. 2003;110:163–169. doi:10.1046/j.1365-2567.2003.01738.x14511229
   PubMed Web of Science ®Google Scholar
• Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013;31:443–473. doi:10.1146/annurev-immunol-032712-09591023298205
   PubMed Web of Science ®Google Scholar
• Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D. Nanomaterial delivery systems for mRNA vaccines. Vaccines (Basel). 2021;9:65.33478109
   PubMed Web of Science ®Google Scholar
• Rahman MM, Zhou N, Huang J. An overview on the development of mRNA-based vaccines and their formulation strategies for improved antigen expression in vivo. Vaccines (Basel). 2021;9:244.33799516
   PubMed Web of Science ®Google Scholar
• Jackson NAC, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines. 2020;5:11. doi:10.1038/s41541-020-0159-832047656
   PubMed Web of Science ®Google Scholar
• Satarker S, Nampoothiri M. Structural proteins in severe acute respiratory syndrome Coronavirus-2. Arch Med Res. 2020;51:482–491. doi:10.1016/j.arcmed.2020.05.01232493627
   PubMed Web of Science ®Google Scholar
• Naqvi AAT, Fatima K, Mohammad T, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165878. doi:10.1016/j.bbadis.2020.16587832544429
   PubMed Web of Science ®Google Scholar
• Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2): an update. Cureus. 2020;12:e7423. doi:10.7759/cureus.742332337143
   PubMed Web of Science ®Google Scholar
• Dhama K, Patel SK, Sharun K, et al. SARS-CoV-2 jumping the species barrier: zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus. Travel Med Infect Dis. 2020;37:101830. doi:10.1016/j.tmaid.2020.10183032755673
   PubMed Web of Science ®Google Scholar
• Haque SM, Ashwaq O, Sarief A, Azad John Mohamed AK. A comprehensive review about SARS-CoV-2. Future Virol. 2020;15:625–648. doi:10.2217/fvl-2020-012433224265
   PubMed Web of Science ®Google Scholar
• Wei J, Hui A-M. Journey of the COVID-19 vaccine from 10 years to 1 year - reassured with real world evidence. Am J Transl Med. 2021;5:1–12.
   Google Scholar
• Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs. 2021;81:495–501. doi:10.1007/s40265-021-01480-733683637
   PubMed Web of Science ®Google Scholar
• Anand P, Stahel VP. Review the safety of Covid-19 mRNA vaccines: a review. Patient Saf Surg. 2021;15:20. doi:10.1186/s13037-021-00291-933933145
   PubMed Web of Science ®Google Scholar
• Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383:2427–2438. doi:10.1056/NEJMoa202843632991794
   PubMed Web of Science ®Google Scholar
• Kyriakidis NC, Lopez-Cortes A, Gonzalez EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6:28. doi:10.1038/s41541-021-00292-w33619260
   PubMed Web of Science ®Google Scholar
• Roth N,   Schön J, Hoffmann D, et al. CV 2 CoV, an enhanced mRNA based SARS-CoV-2 vaccine candidate, supports higher protein expression and improved immunogenicity in rats. 2021. Available from https://www.biorxiv.org/content/10.1101/2021.05.13.443734v1. Accessed December 02, 2021.
   Google Scholar
• Rauch S, Roth N, Schwendt K, et al. mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. NPJ Vaccines. 2021;6:57. doi:10.1038/s41541-021-00311-w33863911
   PubMed Web of Science ®Google Scholar
• Kremsner PG, Guerrero RA, Arana E, et al.Efficacy and Safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomised, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. Lancet. 2021.
   Google Scholar
• Zhang NN, Li X-F, Deng Y-Q, et al. A thermostable mRNA vaccine against COVID-19. Cell. 2020;182:1271–1283 e1216. doi:10.1016/j.cell.2020.07.02432795413
   PubMed Web of Science ®Google Scholar
• Granados-Riveron JT, Aquino-Jarquin G. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2. Biomed Pharmacother. 2021;142:111953. doi:10.1016/j.biopha.2021.11195334343897
   PubMed Web of Science ®Google Scholar
• Laczko D, Hogan MJ, Toulmin SA, et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity. 2020;53:724–732 e727. doi:10.1016/j.immuni.2020.07.01932783919
   PubMed Web of Science ®Google Scholar
• Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586:567–571. doi:10.1038/s41586-020-2622-032756549
   PubMed Web of Science ®Google Scholar
• Funk CD, Laferriere C, Ardakani A. A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic. Front Pharmacol. 2020;11:937. doi:10.3389/fphar.2020.0093732636754
   PubMed Web of Science ®Google Scholar
• Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19:409–424. doi:10.1038/s41579-021-00573-034075212
   PubMed Web of Science ®Google Scholar
• Sanyaolu A, Okorie C, Marinkovic A, et al. The emerging SARS-CoV-2 variants of concern. Ther Adv Infect Dis. 2021;8:20499361211024372. doi:10.1177/2049936121102437234211709
   PubMed Web of Science ®Google Scholar
• Slavov SN, Patané JS, Bezerra RD, et al. Genomic monitoring unveil the early detection of the SARS-CoV-2 B.1.351 (beta) variant (20H/501Y.V2) in Brazil. J Med Virol. 2021;93:6782–6787. doi:10.1002/jmv.2719034241897
   PubMed Web of Science ®Google Scholar
• Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021;596(7871):273–275.34111888
   PubMed Web of Science ®Google Scholar
• Annavajhala MK, Mohri H, Wang P, et al. A novel and expanding SARS-CoV-2 variant, B.1.526, identified in New York. medRxiv. 2021. doi:10.1101/2021.02.23.21252259
   Google Scholar
• Gomez CE, Perdiguero B, Esteban M. Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19. Vaccines (Basel). 2021;9:243.33799505
   PubMed Web of Science ®Google Scholar
• Wu K, Choi A, Koch M, et al. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. bioRxiv. 2021. doi:10.1016/j.vaccine.2021.11.001
   Google Scholar
• Mahase E. Covid-19: moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy. BMJ. 2020;371:m4709. doi:10.1136/bmj.m470933268462
   PubMed Web of Science ®Google Scholar
• Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592:438–443. doi:10.1038/s41586-021-03402-933690265
   PubMed Web of Science ®Google Scholar
• Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021;384:2273–2282. doi:10.1056/NEJMoa210498333882218
   PubMed Web of Science ®Google Scholar
• Riley LE. mRNA Covid-19 vaccines in pregnant women. N Engl J Med. 2021;384:2342–2343. doi:10.1056/NEJMe210707034133864
   PubMed Web of Science ®Google Scholar
• Fooks AR, Cliquet F, Finke S, et al. Rabies. Nat Rev Dis Primers. 2017;3:17091. doi:10.1038/nrdp.2017.9129188797
   PubMed Web of Science ®Google Scholar
• Davis BM, Rall GF, Schnell MJ. Everything you always wanted to know about rabies virus (but were afraid to ask). Annu Rev Virol. 2015;2:451–471. doi:10.1146/annurev-virology-100114-05515726958924
   PubMed Web of Science ®Google Scholar
• Hampson K, Coudeville L, Lembo T, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015;9:e0003709. doi:10.1371/journal.pntd.000370925881058
   PubMed Web of Science ®Google Scholar
• Aldrich C, Leroux–Roels I, Huang KB, et al. Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial. Vaccine. 2021;39:1310–1318. doi:10.1016/j.vaccine.2020.12.07033487468
   PubMed Web of Science ®Google Scholar
• Armbruster N, Jasny E, Petsch B. Advances in RNA vaccines for preventive indications: a case study of a vaccine against rabies. Vaccines (Basel). 2019;7:996–998. doi:10.3390/vaccines7040132
   Web of Science ®Google Scholar
• Te Velthuis AJ, Fodor E. Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis. Nat Rev Microbiol. 2016;14:479–493. doi:10.1038/nrmicro.2016.8727396566
   PubMed Web of Science ®Google Scholar
• Bouvier NM, Palese P. The biology of influenza viruses. Vaccine. 2008;26(Suppl 4):D49–53. doi:10.1016/j.vaccine.2008.07.03919230160
   PubMed Web of Science ®Google Scholar
• Krammer F, Smith GJD, Fouchier RAM, et al. Influenza. Nat Rev Dis Primers. 2018;4:3. doi:10.1038/s41572-018-0002-y29955068
   PubMed Web of Science ®Google Scholar
• Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis. 2006;12:15–22. doi:10.3201/eid1209.05-097916494711
   PubMed Web of Science ®Google Scholar
• Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci U S A. 2017;114:12578–12583. doi:10.1073/pnas.171237711429109276
   PubMed Web of Science ®Google Scholar
• Rockman S, Laurie KL, Parkes S, Wheatley A, Barr IG. New technologies for influenza vaccines. Microorganisms. 2020;8:1745. doi:10.3390/microorganisms8111745
   Web of Science ®Google Scholar
• Zhang JJ, Dong X, Cao -Y-Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75:1730–1741. doi:10.1111/all.1423832077115
   PubMed Web of Science ®Google Scholar
• Feldman RA, Fuhr R, Smolenov I, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37:3326–3334. doi:10.1016/j.vaccine.2019.04.07431079849
   PubMed Web of Science ®Google Scholar
• Collins PL, Fearns R, Graham BS. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol. 2013;372:3–38. doi:10.1007/978-3-642-38919-1_124362682
   PubMed Web of Science ®Google Scholar
• Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol. 2019;17:233–245. doi:10.1038/s41579-019-0149-x30723301
   PubMed Web of Science ®Google Scholar
• Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev. 2014;35:519–530. doi:10.1542/pir.35-12-51925452661
   PubMedGoogle Scholar
• Aliprantis AO, Shaw CA, Griffin P, et al. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Hum Vaccin Immunother. 2021;17:1248–1261. doi:10.1080/21645515.2020.182989933121346
   PubMed Web of Science ®Google Scholar
• Crowe JE, Williams JV. Paramyxoviruses: respiratory syncytial virus and human metapneumovirus. In Viral Infections of Humans. Springer; 2014;601–627.
   Google Scholar
• Bailly JE, McAuliffe JM, Durbin AP, et al. A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates. J Virol. 2000;74:3188–3195. doi:10.1128/JVI.74.7.3188-3195.200010708435
   PubMed Web of Science ®Google Scholar
• Shaw C, Lee H, Knightly C, et al. 2754. Phase 1 trial of an mRNA-based combination vaccine against hMPV and PIV3. Open Forum Infect Dis. 2019;6:S970–S970. doi:10.1093/ofid/ofz360.2431
   Google Scholar
• Jeffries AM, Nitika T, Marriott I. The intracellular DNA sensors cGAS and IFI16 do not mediate effective antiviral immune responses to HSV-1 in human microglial cells. J Neurovirol. 2020;26:544–555. doi:10.1007/s13365-020-00852-132488842
   PubMed Web of Science ®Google Scholar
• Schottstedt V, Blümel J, Burger R, et al. Human cytomegalovirus (HCMV) - revised. Transfus Med Hemother. 2010;37:365–375.21483467
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Wang D, Oualim A, et al. The status of vaccine development against the human cytomegalovirus. J Infect Dis. 2020;221:S113–S122. doi:10.1093/infdis/jiz44732134478
   PubMed Web of Science ®Google Scholar
• Anderholm KM, Bierle CJ, Schleiss MR. Cytomegalovirus vaccines: current status and future prospects. Drugs. 2016;76:1625–1645. doi:10.1007/s40265-016-0653-527882457
   PubMed Web of Science ®Google Scholar
• Noorbakhsh F, Abdolmohammadi K, Fatahi Y, et al. Zika virus infection, basic and clinical aspects: a review article. Iran J Public Health. 2019;48:20–31.30847308
   PubMed Web of Science ®Google Scholar
• Richner JM, Himansu S, Dowd KA, et al. Modified mRNA vaccines protect against zika virus infection. Cell. 2017;168:1114–1125 e1110. doi:10.1016/j.cell.2017.02.01728222903
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Pelc RS, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017;543:248–251. doi:10.1038/nature2142828151488
   PubMed Web of Science ®Google Scholar
• Poland GA, Kennedy RB, Ovsyannikova IG, et al. Development of vaccines against Zika virus. Lancet Infect Dis. 2018;18:e211–e219. doi:10.1016/S1473-3099(18)30063-X29396004
   PubMed Web of Science ®Google Scholar
• Cohen JI, Fauci AS, Varmus H, Nabel GJ. Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med. 2011;3:107fs107. doi:10.1126/scitranslmed.3002878
   Web of Science ®Google Scholar
• Fugl A, Andersen CL. Epstein-Barr virus and its association with disease - a review of relevance to general practice. BMC Fam Pract. 2019;20:62. doi:10.1186/s12875-019-0954-331088382
   PubMed Web of Science ®Google Scholar
• Chand HS, Vazquez-Guillamet R, Royer C, et al. Cigarette smoke and HIV synergistically affect lung pathology in cynomolgus macaques. J Clin Invest. 2018;128:5428–5433. doi:10.1172/JCI12193530277472
   PubMed Web of Science ®Google Scholar
• German Advisory Committee Blood. Human Immunodeficiency Virus (HIV). Transfus Med Hemother. 2016;43:203–222. doi:10.1159/00044585227403093
   PubMed Web of Science ®Google Scholar
• Esteban I, Pastor-Quiñones C, Usero L, et al. In the era of mRNA vaccines, is there any hope for HIV functional cure? Viruses. 2021;13:501. doi:10.3390/v1303050133803790
   PubMed Web of Science ®Google Scholar
• Emmer KL, Wieczorek L, Tuyishime S, et al. Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140. AIDS. 2016;30:2405–2414. doi:10.1097/QAD.000000000000122427525550
   PubMed Web of Science ®Google Scholar
• Spearman P, Lally MA, Elizaga M, et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis. 2011;203:1165–1173. doi:10.1093/infdis/jiq17521451004
   PubMed Web of Science ®Google Scholar
• Pardi N, Secreto AJ, Shan X, et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun. 2017;8:14630. doi:10.1038/ncomms1463028251988
   PubMed Web of Science ®Google Scholar
• Parks T, Barrett L, Jones N. Invasive streptococcal disease: a review for clinicians. Br Med Bull. 2015;115:77–89. doi:10.1093/bmb/ldv02726209784
   PubMed Web of Science ®Google Scholar
• Kourtis AP, Appelgren K, Chevalier MS, McElroy A. Ebola virus disease: focus on children. Pediatr Infect Dis J. 2015;34:893–897. doi:10.1097/INF.000000000000070725831417
   PubMed Web of Science ®Google Scholar
• Matua GA, Van der Wal DM, Locsin RC. Ebolavirus and haemorrhagic syndrome. Sultan Qaboos Univ Med J. 2015;15:e171–176.26052448
   PubMedGoogle Scholar
• Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med. 2016;374:1647–1660. doi:10.1056/NEJMoa150292425830326
   PubMed Web of Science ®Google Scholar
• Meyer M, Huang E, Yuzhakov O, et al. Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease. J Infect Dis. 2018;217:451–455. doi:10.1093/infdis/jix59229281112
   PubMed Web of Science ®Google Scholar
• Rosa SS, Prazeres DMF, Azevedo AM, Marques MPC. mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine. 2021;39:2190–2200. doi:10.1016/j.vaccine.2021.03.03833771389
   PubMed Web of Science ®Google Scholar
• Abbasi J. COVID-19 and mRNA vaccines-first large test for a new approach. JAMA. 2020;324:1125–1127. doi:10.1001/jama.2020.1686632880613
   PubMed Web of Science ®Google Scholar
• Wadhwa A, Aljabbari A, Lokras A, Foged C, Thakur A. Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics. 2020;12:102. doi:10.3390/pharmaceutics12020102
   PubMed Web of Science ®Google Scholar
• Xu S, Yang K, Li R, Zhang L. mRNA vaccine era-mechanisms, drug platform and clinical prospection. Int J Mol Sci. 2020;21:6582. doi:10.3390/ijms21186582
   PubMed Web of Science ®Google Scholar
• Bettini E, Locci M. SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond. Vaccines (Basel). 2021;9. doi:10.3390/vaccines9020147
   PubMed Web of Science ®Google Scholar
• Manzoni C, Kia DA, Vandrovcova J, et al. Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences. Brief Bioinform. 2018;19:286–302. doi:10.1093/bib/bbw11427881428
   PubMed Web of Science ®Google Scholar
• Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011;3:73–78. doi:10.4103/0974-777X.7729921572612
   PubMedGoogle Scholar
• Gebre MS, Rauch S, Roth N, et al. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Nature. 2021. doi:10.1038/s41586-021-04231-6
   Web of Science ®Google Scholar